Short Interest in Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) Decreases By 84.1%

Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) was the target of a large drop in short interest in July. As of July 31st, there was short interest totaling 55,796 shares, a drop of 84.1% from the July 15th total of 350,806 shares. Based on an average daily volume of 2,500 shares, the days-to-cover ratio is currently 22.3 days.

Wall Street Analyst Weigh In

Separately, Danske started coverage on Hansa Biopharma AB (publ) in a research report on Tuesday, June 16th. They set a “buy” rating on the stock. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy”.

Hansa Biopharma AB (publ) Stock Performance

OTCMKTS:HNSBF opened at $3.70 on Wednesday. The stock’s fifty day moving average is $3.04 and its two-hundred day moving average is $2.95. Hansa Biopharma AB has a 52 week low of $2.90 and a 52 week high of $3.70.

Hansa Biopharma AB (publ) Company Profile

Hansa Biopharma AB (publ) is a clinical‐stage biopharmaceutical company headquartered in Lund, Sweden, focused on the development and commercialization of precision immunomodulatory therapies for rare diseases. The company’s proprietary platform centers on highly specific bacterial enzymes that selectively cleave immunoglobulin G (IgG) antibodies, offering a novel approach to desensitization and immunomodulation in transplant and autoimmune settings.

The lead asset, imlifidase (Idefirix), is an enzyme therapeutic designed to rapidly inactivate donor‐specific antibodies in highly sensitized kidney transplant patients.